New anti-HIV drugs in development

Proj Inf Perspect. 1999 Sep:(28):4-8.

Abstract

AIDS: Updates are provided for new anti-HIV drugs currently in development. ABT-378, Tipranavir, and DMP-450 are among the new protease inhibitors discussed. Drugs from other classes that are discussed include emivirine (Coactinon, formerly MKC-442), FTC (emtricitabine, Coviracil), adefovir (Preveon), and pentafuside (T-20). A small study has found that women using Ritonavir (Norvir) may be at a greater risk for anemia (a decrease in red blood cells), caused by excessive menstrual bleeding or hypermenorrhea. New formulations of Ritonavir and ddI (Didanosine, Videx) are described.

Publication types

  • Newspaper Article

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Anti-HIV Agents / therapeutic use*
  • Capsules
  • Carbamates
  • Chemistry, Pharmaceutical
  • Didanosine / administration & dosage
  • Drug Synergism
  • Drug Therapy, Combination
  • Drugs, Investigational
  • Female
  • Furans
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage*
  • HIV Protease Inhibitors / adverse effects
  • Humans
  • Lopinavir
  • Menorrhagia / etiology*
  • Pyrimidinones / administration & dosage*
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Ritonavir / administration & dosage*
  • Ritonavir / adverse effects
  • Sulfonamides / administration & dosage

Substances

  • Anti-HIV Agents
  • Capsules
  • Carbamates
  • Drugs, Investigational
  • Furans
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • Sulfonamides
  • Lopinavir
  • amprenavir
  • Didanosine
  • Ritonavir